The Definitive Industry Reference, this report is a “must read” for anyone involved in deal making who wants to get the maximum value from their next deal.

"The report sets out to give the reader a full insight into determining valuation and royalties and the huge impact that these terms can have on deals and their ultimate survival."

Dr Fintan Walton,
CEO of PharmaVentures

The content has been formulated by leveraging over 15 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making, and in response to valued feedback from our extensive market research. This report follows on from the publication of previous top selling reports on the topic of royalty rates.

• Clear guidance on the best methodologies to use when calculating Royalty Rates to assist with vital decision making 
• Opinions and advice from leading industry deal makers on how to calculate Royalty Rates 
• Contextual information – The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: “What do royalties mean in terms of value?” and “Where do royalties fit within the deal?” 
• More case studies – PharmaVentures highlights the issues and pitfalls so that you can avoid them

Click here to view the full table of contents

The report, written by Bird & Bird's leading lawyers, sets out the essential issues concerning the intellectual property regime and the application of competition law in the pharmaceuticals sector, and the sector-specific regulatory provisions affecting competition.

The resulting case law both at EU level and at national level implementing the EU rules on competition and the related regulatory developments are central to the strategic decisions of pharmaceuticals suppliers.

Looking at leading cases within the pharmaceuticals sector, involving companies such as GlaxoSmithKline, Boehringer Ingelheim, Bayer, Organon, Johnson & Johnson, AstraZeneca, Napp Pharmaceuticals and Genzyme to illustrate the key points, the report examines essential issues, including the following:

• How legislation and case law has set out limits in various areas on the extents to which intellectual property owners can enforce their patents
• Parallel importation under the EC rules on free circulation of goods and the EC competition rules, agreements and conduct restricting parallel imports and exports
• Meaning of an agreement under the EC competition rules
• Conduct of dominant suppliers with regard to pricing issues
• Commission guidelines on the application of competition rules to R&D collaboration agreements
• Effect of regulation on technology licensing, marketing and distribution agreements

UK and EC competition authorities' commitment to private enforcement of the competition rules to combat cartels

Click here to view the full table of contents

The report covers those essential market changing initiatives which make tomorrow’s drug market different from today’s. Successful deal making has accurate valuation at its heart. Anything that impacts a drugs ability to achieve in the future a fair and profitable market price impacts its value today. The current market is more challenging than ever before. Payer-driven price negotiation for reimbursement, and cost-containment programmes to control prescribing both challenge the traditional pricing model the industry has used to generate valuable R&D resource to further the search for innovation and better disease control.

Click here to view the executive summary

With analysis of deal making trends, and discussion of the top deals by therapy area as well as their impact on the market-place, this resource will be of immense value to those who need to stay up-to-date on the developments in their area, those planning to do deals in other therapy areas and those interested in understanding how the deals made in 2006 are likely to affect their firm's business strategy in 2007. To add further value, the report is accompanied by interviews with industry experts. Access to these interviews will be provided online.

Click here to view the executive summary

This publication provides an essential grounding in how to use accepted and reliable methods for valuing pharmaceutical and biotech projects. Whether you are about to negotiate a licensing deal or need to perform a rigorous portfolio review, it is vital that you understand both the value of a project today and how that value can be built over time.

The methods presented here provide answers to both questions through the combination of historical analysis of what the market has been willing to pay for similar products and technologies, and forward-looking projections that explicitly handle the issues of risk, time, cost and reward.

Potential elements of deals are also discussed, as are the appropriate levels of risk and reward sharing, and the significance of individual company needs and preferences. When incorporated into the valuation models that have been built, these elements will permit the development of deal structures that are attractive to both sides.

Click here to view the executive summary

This reference guide provides deal makers with answers to many of the questions that arise in specific deal situations. It is a comprehensive source of information relating to all deal structures and is the ultimate reference source for anyone involved in business development or licensing. Accompanied by an online access, each specific agreement or structure type is illustrated with current case studies.

Click here to view the executive summary

Published reports include:
PharmaDeals® Deal Making Spotlight Reports
Deal Making Spotlight on Pfizer
Deal Making Spotlight on sanofi-aventis
Deal Making Spotlight on GlaxoSmithKline
Deal Making Spotlight on Johnson & Johnson
Deal Making Spotlight on Novartis

Detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy.

Click here to view the table of contents

• The virus and its history
• Key industry insight
• An analysis of the market
• Summary of influenza-related deals 

View the table of contents

Dedicated to the drug delivery sector, this report offers a concise and focused means of assessing and benchmarking drug delivery deal making activity over the past 9 years. It details valuation methodologies and explores effective deal structuring to ensure maximum returns. It is a critical report for all those involved in deal making across both the pharmaceutical and biotechnology sectors. This edition provides an up-to-date perspective of the drug delivery sector. It includes over 1400 drug delivery deals, over 50 drug delivery contracts and the latest company information.

Click here to view the executive summary

This report provides in-depth information and practical advice relating to the partnering process. Based on PharmaVentures' experiences of working with pharmaceutical and biotechnology companies worldwide, this comprehensive report provides an insight into the challenges and rewards of the partnering process. The report includes quotations documenting industry-partnering experiences, and is a must read for anyone needing to complete & manage deals.

Click here to view the executive summary